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M-B Vidriales3, R García-Sanz3, C Jimenez3, M González3, J Martínez-López6, A Corral-Mateos1, G-E Grigore7, R Fluxá7, R Pontes8,
J Caetano9, L Sedek10, M-C del Cañizo3, J Bladé11, J-J Lahuerta6, C Aguilar12, A Bárez13, A García-Mateo14, J Labrador15, P Leoz1,
C Aguilera-Sanz16, J San-Miguel2,20, M-V Mateos3,20, B Durie17,21, JJM van Dongen5,18,21 and A Orfao1,21
Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of
complete response (CR) in bone marrow (BM) of multiple myeloma (MM) after therapy. However, current ﬂow-MRD has lower
sensitivity than molecular methods and lacks standardization. Here we report on a novel next generation ﬂow (NGF) approach for
highly sensitive and standardized MRD detection in MM. An optimized 2-tube 8-color antibody panel was constructed in ﬁve cycles
of design-evaluation-redesign. In addition, a bulk-lysis procedure was established for acquisition of ⩾ 107 cells/sample, and novel
software tools were constructed for automatic plasma cell gating. Multicenter evaluation of 110 follow-up BM from MM patients in
very good partial response (VGPR) or CR showed a higher sensitivity for NGF-MRD vs conventional 8-color ﬂow-MRD -MRD-positive
rate of 47 vs 34% (P= 0.003)-. Thus, 25% of patients classiﬁed as MRD-negative by conventional 8-color ﬂow were MRD-positive by
NGF, translating into a signiﬁcantly longer progression-free survival for MRD-negative vs MRD-positive CR patients by NGF (75%
progression-free survival not reached vs 7 months; P= 0.02). This study establishes EuroFlow-based NGF as a highly sensitive, fully
standardized approach for MRD detection in MM which overcomes the major limitations of conventional ﬂow-MRD methods and is
ready for implementation in routine diagnostics.
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INTRODUCTION
In recent years, the landscape of treatment of multiple myeloma
(MM) has substantially changed1–4 leading to signiﬁcantly increased
complete response (CR) rates and survival.5–11 Therefore, CR has
become a major goal in newly diagnosed MM, even in aged
patients.5,12–15 Despite these advances, most CR patients will
ultimately relapse.7,10 Consequently, better insight in depth of
treatment response is required and more sensitive methods
are needed for detection of minimal residual disease (MRD),
particularly in cases that reached CR and stringent CR (sCR).16
Conventional 4–8-color ﬂow cytometry,17–24 and to a lesser
extent also allele-speciﬁc oligonucleotide quantitative PCR
(ASOqPCR) and next generation sequencing (NGS),25–29 are
progressively being used to monitor MRD in bone marrow (BM)
of MM after therapy.16,30 These studies conﬁrmed the relevance of
MRD measurements for identiﬁcation of MM patients at higher risk
of relapse.16,22 However, despite the greater sensitivity of the MRD
approaches (vs classical CR/sCR criteria), identiﬁcation among
MRD− cases of patients that will eventually relapse vs those who
are potentially cured still remains a challenge, implying that more
sensitive MRD approaches are needed.16,31
High sensitivity and broad applicability have both become
mandatory requirements for MRD monitoring in MM.16 Early
studies have shown that conventional 4–6-color ﬂow-MRD is
applicable in virtually all MM patients (⩾ 95%), whereas ASOqPCR
and NGS have a more restricted applicability (50–90% of cases),
mainly due to the high number of somatic hypermutations, which
cause variable levels of primer annealing with unpredictable
ampliﬁcation/quantitation results.16,25,32–34 However, the sensitivity
of conventional ﬂow-MRD (o10−4) remains (systematically) lower
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than that of ASOqPCR and NGS (o10− 4–10− 6).25,26,29,35 More
recently, several studies in MM have shown that conventional
8-color ﬂow-MRD assays have an increased sensitivity – limit of
detection (LOD) of between o10− 4 and o10− 5-, leading to a
signiﬁcantly improved prediction of outcome.24,36 However,
current ﬂow-MRD assays and NGS still suffer from a major
limitation: lack of standardization.37 Actually, different markers
and antibody panels, distinct numbers of cells measured, and
highly variable criteria for MRD positivity are currently applied
worldwide.38,39 Therefore, standardization efforts have been made
and consensus recommendations and guidelines have been
recently proposed.40–42 However, such consensus recommenda-
tions still rely on subjective ‘expert-shared’ knowledge and
experience, and do not completely solve the lack of technical
standardization, whereas prospectively validated ﬂow-MRD
approaches are still missing.39
Here we report on the design of a EuroFlow-based next generation
ﬂow (NGF) approach for highly sensitive and standardized detection
of MRD in MM, and the results of its validation vs a conventional
8-color ﬂow-MRD method24 and NGS. The novel NGF-MRD approach
takes advantage of innovative tools and procedures recently
developed by the EuroFlow Consortium for sample preparation,
antibody panel construction (including choice of type of antibody
and ﬂuorochrome), and automatic identiﬁcation of plasma cells
(PC) against reference databases of normal and patient BM.43–46
Prospective validation of the whole procedure at two distinct centers
conﬁrmed its robustness and signiﬁcantly greater sensitivity vs
conventional 8-color ﬂow-MRD approaches, comparable to current
NGS methods, with an improved prediction of patient outcome.
SUBJECTS AND METHODS
Patients, controls and samples
A total of 375 BM and 10 peripheral blood EDTA-anticoagulated samples
from 53 controls and 332 adult plasma cell disorder (PCD) patients, were
studied (Supplementary Table 1) to design Version 1 of the MM-MRD
antibody panel (n=94; 31 normal/reactive and 63 MM studied at
diagnosis), to compare the performance of antibody reagents evaluated
in Versions 2–5 of the NGF-MRD panel (19 BM diagnostic patient samples),
to evaluate distinct sample preparation protocols (n=10 peripheral blood
and 8 BM samples) and to validate NGF (Version 5) against conventional 8-
color ﬂow-MRD -n=244 consecutively recruited samples corresponding to
16 healthy donors, 66 PCD samples studied at diagnosis and 162 MM
patient samples investigated during follow-up, including 110 follow-up BM
samples from MM patients evaluated at ⩾ very good partial response
(VGPR): 39 VGPR; 52 CR; and 19 sCR cases-. Twenty-one ⩾ VGPR BM
samples and 10 additional BM samples -22/31 with very low MRD levels
(⩽10− 4)- were further used to blindly compare NGF vs NGS (Supple-
mentary Table 1).
The study was approved by the local ethics committees and written
informed consent was given by each donor according to the Declaration of
Helsinki. All samples were processed at each participating center (USAL/
HUSAL, UNAV, EMC, UNIKIEL, IPOLFG, SUM) within 24 h after collection.
Immunophenotypic studies for selection of plasma cell
(PC)-associated markers
BM samples used to establish Version 1 (Table 1) of the MM-MRD panel
were stained with the EuroFlow PCD 8-color panel for a total of 12 different
markers (CD38, CD138, CD45, CD19, CD27, CD28, CD56, CD81, CD117,
CyIgκ, CyIgλ and β2-microglobulin), using previously described EuroFlow
sample preparation protocols.44,45 For data analysis, events from both
8-color tubes (per sample) were merged and the values of all parameters
measured per tube were mathematically calculated for the individual PC
events using the merge and calculation functions of the Inﬁnicyt software
(Cytognos SL, Salamanca, Spain).43–45 Subsequently, phenotypic data on
normal PC (nPC) from 31 normal/reactive BM samples were merged in a
reference database. PC were identiﬁed based on their unique pattern of
expression of CD38, CD138, CD45 and light scatter features, following
consensus recommendations.40–42 Principal component analysis44,45 of
single PC events was used to compare the reference database of nPC vs
aberrant/clonal PC (aPC) from each of 63 MM BM studied at diagnosis, to
identify the most discriminating markers that distinguished between
(reference) nPCs and aPC from individual MM patients (Figure 1), and
establish the applicability of the method. Additionally, CD200 expression
was also evaluated on PC in a subset of 28 MM.
Results on the comparison between antibody reagents directed against the
same marker (Supplementary Table 2), was based on their staining proﬁles on
nPC vs aPC (vs other non-PC BM populations) as deﬁned by median
ﬂuorescence intensity (range: 0–262,144 arbitrary units) and stain index values,
as previously described47 (Supplementary text). The EuroFlow reagent evalua-
tion criteria44 were used to discard or accept individual reagents: (i) increased
background ﬂuorescence; (ii) dim ﬂuorescence of PCs vs other BM populations
(CD38, CD138, CyIgκ+ or CyIgλ+) or the positive vs negative BM reference
populations (CD19, CD27, CD56, CD45, CD81 vs CD117) and (iii) interaction
with the staining pattern of other reagents.
Design and evaluation of sample preparation protocols
For the evaluation of different sample preparation protocols, eight BM and 10
peripheral blood samples were stained in parallel with the CD138-HV450
CD45-PacO CD56-PE CD5-PerCPCy5.5 CD19-PECy7 CD3-APC antibody combi-
nation under ﬁve different conditions: (i) the EuroFlow standard operating
procedure (SOP) for staining of 50 μl of sample with cell surface markers,44
and (ii) four different ammonium chloride-based bulk-lysis procedures
followed by staining of 5×106 cells in 100 μl/tube (ﬁnal concentration of
5×104 cells/μl), as described in detail in the Supplementary text.
Validation of the NGF MM-MRD method
Overall, 228 MM diagnostic (n= 66) and follow-up (n=162) BM samples
(n=110 in VGPR or CR/sCR) were evaluated in parallel with the NGF MRD
approach vs local routine ﬂow-MRD methods (that is, conventional 8-color
ﬂow-MRD technique).24 Detailed description of these BM samples, related
patient clinical data, disease status and time points at evaluation is
provided in Supplementary Tables 1, 3 and 4. Brieﬂy, conventional ﬂow-
MRD was based on staining of 300 μl of whole BM with a single 8-color
antibody combination (CD45-PacB CD138-OC515 CD38-FITC CD56-PE
CD27-PerCPCy5.5 CD19-PECy7 CD117-APC CD81-APCH7), as previously
described.24 In turn, for the NGF approach a median volume of 1.5 ± 1.3 ml
(range: 0.1–5.3 ml) was employed adding up to a median total sample
volume of 1.8 ml (maximum of 5.6 ml). PC populations that coexisted in
individual BM samples were identiﬁed based on a combination of the
CD38, CD138, CD45 PC-associated markers and light scatter characteristics,
the presence vs absence of myeloma-associated phenotypes, plus CyIg
light chain restriction in case of NGF, as described elsewhere.48 According
to consensus recommendations,42 the limit of quantitation and the LOD of
the NGF MRD method was calculated at o5× 10− 6 and o2 × 10− 6 aPC,
based on the identiﬁcation of ⩾ 50 and ⩾ 20 aPC among 107 events,
respectively. More detailed information about instrument conditions, data
acquisition and analysis, and the speciﬁc reagents used in the present
study is provided as Supplementary Material.
Automatic identiﬁcation and enumeration of aPC was performed in 110
MM BM follow-up (VGPR or CR/sCR) samples using the automatic gating
function of the Inﬁnicyt software and previously described procedures,49,50
and the results were compared against the conventional expert-guided
PC-identiﬁcation/gating approach. For automatic gating, a database
consisting of a subset of 14 normal BM samples stained with Version 5
of the antibody panel was constructed and used.50
In a subset of 31 MM follow-up BM samples with low MRD levels (for
example, ⩽ 10− 4) in which enough DNA was available, MRD was also
evaluated by NGS. For this purpose, patient-speciﬁc VDJH rearrangements
were ampliﬁed and directly sequenced from DNA extracted from
diagnostic samples using the DNAzol reagent (MRC, Cincinnati, OH, USA)
and IGHV family-speciﬁc primers that covered framework regions 1 (FR1)
and FR2, plus a JH consensus primer, as described elsewhere.26,32 VDJH
rearrangements identiﬁed at diagnosis were used as MRD-targeted
sequences for subsequent follow-up samples. Follow-up DNA samples
were ampliﬁed using the LymphoTrack IGH Assay (InVivoScribe Technol-
ogies, San Diego, CA, USA) and sequenced in an Illumina MiSeq platform
(Illumina, San Diego, CA, USA). To all reactions, a known amount of DNA
from the MWCL-1 cell line was added as reference control for cell
enumeration. The Fastq ﬁles generated were analyzed with the Lympho-
Track/MiSeq Software (InVivoScribe/Illumina). The number of MRD cells
was calculated from the number of reads for the diagnostic VDJH target
rearrangements and the number of reads of the reference rearrangement;
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percentage MRD was calculated upon dividing the number (×100) of MRD
cells by the total number of cells in the reaction.
Statistical methods
Number of samples required in the assay development and validation
experiments were calculated using the hypothesis contrast strategy for the
comparison of paired quantitative data (EPIDAT 4.0 software, Consellería
de Sanidade, Xunta de Galicia, Spain). To evaluate the distribution of MRD
data, the Kolmogorov–Smirnov test was used. The Wilcoxon or Friedman
tests and the Mann–Whitney U or the Kruskal–Wallis tests were used to
assess the (two-sided) statistical signiﬁcance of differences observed
between ⩾ 2 groups for paired and unpaired variables, respectively. For
correlation studies, the (two-sided) Spearman’s rho (ρ) for non-parametric
Figure 1. Diagram illustrating the process used for the selection and evaluation of markers for the NGF MM MRD panel. Left and lower right
panels show the sequential steps followed to select those markers providing the best resolution between aPCs and nPC, including principal
component 1 (PC1) vs PC2 —automatic population separator (APS1)— plots illustrating the described comparisons for steps 1, 2 and 4,
respectively. (right; a) An APS1 plot corresponding to the simultaneous evaluation of 31 normal/reactive BM samples vs all 63 MM patients
studied at diagnosis, in which the resolution power of the EuroFlow diagnostic PCD antibody panel combination is illustrated. Please note that
PC from ﬁve samples (highlighted by the black arrows) showed suboptimal separation in the overall comparison; nonetheless, when
individually compared vs the normal/reactive reference PC pool (b–f), these cases also showed sufﬁcient phenotypic discrimination from nPC.
Markers contributing to PC1 (and their percentage contribution) for each panel on the right include: (a) CD19(20%), CD56(17%), CD81(13%),
CD45(11%), CD117(10%), CD27(8%), CyIgλ(5%), CD38(5%), CyIgκ(4%), β2 micro(3%), CD138(3%), CD28(1%); (b) CyIgκ(27%), CyIgλ(13%), β2
micro(12%), CD38(11%), CD56(10%), CD138(7%), CD28(16%), CD45(4%), CD27(4%), CD117(4%), CD19(2%), CD81(0%); (c) CyIgκ(20%), CD45
(16%), CD56(11%), CD28(10%), CD19(10%), CD27(8%), CD117(6%), CD81(6%), CD38(6%), CyIgλ(4%), CD138(3%), β2 micro(0%); (d), CD19(29%),
β2 micro(13%), CyIgκ(13%), CD56(13%), CD45(11%), CD38(5%), CD27(4%), CyIgλ(3%), CD28(3%), CD138(2%), CD117(2%), CD81(2%); (e) CD19
(23%), β2 micro(13%), CD45(12%), CyIgλ(11%), CD81(9%), CD56(7%), CyIgκ(6%), CD38(6%), CD28(4%), CD138(4%), CD27(4%), CD117(1%);
(f) CD19(20%), CD117(19%), CD81(14%), CD45(13%), CD56(12%), CyIgλ(9%), β2 micro(6%), CD38(3%), CD27(2%), CD28(1%), CD138(1%), CyIgκ
(0%). In all PC1 vs PC2 plots, solid circles represent median values for the 12 ﬂuorescence-associated parameters evaluated, inner (dotted) and
outer (solid) lines represent the ﬁrst and second standard deviations for individual PC. nPC populations are depicted in green while aPC are
shown as red dots, circles and lines, respectively.
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paired data was employed. The Kaplan–Meier method and the (two-sided)
log-rank test were used to plot and compare progression-free survival
(PFS) curves. PFS was deﬁned as the time from MRD assessment to either
disease progression or the last follow-up visit. Statistical signiﬁcance was
set at Po0.05. All samples evaluated were blindly analyzed during the
experimental phase.
RESULTS
Antibody panel construction for optimal identiﬁcation of MM
plasma cells at MRD levels
Comparison of the whole immunophenotypic proﬁle of aPC from
individual MM patients (n= 63) vs the normal/reactive BM PC
database (n= 31) showed multiple aberrant phenotypes in every
case (Figure 1). Eight of the 12 markers evaluated contributed
most frequently to the discrimination between aPC and nPC based
on principal component analysis of single PC phenotypes: CD19
(97% of cases); CD45 (89%); CD56 (86%); CD81 (86%); CyIgλ (73%);
CD27 (71%); CD117 (60%); and CyIgκ (56%). Re-evaluation of the
utility of the combination of these eight top markers alone in the
same 63 MM BM conﬁrmed clear-cut distinction between aPC and
nPC in the database, in every case. Consequently, the six surface
membrane markers of this list, plus the CD138 and CD38
PC-identiﬁcation markers, were selected to be combined in a
single 8-color tube. In a second 8-color antibody combination,
CyIgκ and CyIgλ were added to the CD138 and CD38, together
with CD229 as an extra PC-identiﬁcation antigen, plus the three
most informative markers (CD19, CD45, CD56), for parallel
conﬁrmation of immunoglobulin light chain (κ vs λ) restriction
of PC suspected to be (clonal) myeloma PC (Versions 2 and 3).
Optimization of the two 8-color MM MRD antibody combinations
Subsequently, evaluation of the same 63 MM diagnostic samples
using the two 8-color antibody combinations selected above,
but focusing now on the detection of minimal numbers (that is,
0.02–0.1%) of MM PC, was performed using virtual (software)
dilution experiments of decreasing numbers of PC in the nPC
reference database, as previously described.51 This revealed
suboptimal reagent performance (for example dim staining) for
two ﬂuorochrome positions (that is, CD138-PacO and CD81/CyIgλ-
APCH7).
From this initial Version 1, until the ﬁnal version of the antibody
panel (Version 5), four other versions of different ﬂuorochrome-
conjugated reagents of the same markers were tested (Table 1) as
described in detail in Supplementary text. Brieﬂy, in Version 2, the
suboptimal CD138-PacO reagent was replaced by CD138-HV500C;
in Version 3, suboptimal CD81-APCH7 and CyIgλ-APCH7 reagents
were both replaced by CD81-APCC750 and CyIgλ-APCC750. For
Version 4, the CD138-HV500C reagent found to be still suboptimal
was replaced, together with the CD27-PerCPCy5.5 and CD45-PacB
ﬂuorochrome positions, by CD138-HV450, CD27-HV500C and
CD45-PerCPCy5.5, respectively. Finally, in Version 5, CD138-
HV450, CD27-HV500C and CD38-FITC were replaced by the
optimized CD138-BV421 and CD27-BV510 conjugates, and the
multi-epitope CD38-FITC antibody, respectively. The later
CD38 reagent showed an equivalent performance in diagnostic
MM samples to that of the original CD38 antibody clone,
but a much better resolution in BM samples from MM patients
who had received Daratumumab therapy (Supplementary
Figure 1). Moreover, CD229 was excluded from tube 2,
since this marker did not identify all aPC in 4/49 (8%) MM cases
tested, and it was not speciﬁc for PC, being also (strongly)
expressed on plasmacytoid dendritic cells and a subset of
lymphocytes.52
Evaluation of sample preparation protocols
Overall, bulk-lysis procedures were systematically associated with
acquisition of a signiﬁcantly (Po0.05) greater number of cells vs
the conventional BD FACS Lysing Solution (BD Biosciences, San
Jose, CA, USA) based (FACS-lyse) SOP (Supplementary Figure 2A).
However, all bulk-lysis conditions but that using low bovine serum
albumin (0.5% bovine serum albumin) and a FACS-lysing-ﬁxation
step (protocol A1 in Supplementary Figure 2), showed a
signiﬁcantly higher proportion of debris and dead cells (Po0.05
Table 1. Multiple myeloma NGF-MRD: 8- and 10-color antibody panels evaluated from the ﬁrst (Version 1) to the ﬁnal version (Version 5)
8-color panel version Tube PacB PacO FITC PE PerCPCy5.5 PECy7 APC APCH7
1 1 CD45 CD138 CD38 CD56 CD27 CD19 CD117 CD81
2 CD45 CD138 CD38 CyIgκ CyIgλ
HV500C
2 1 CD45 CD138 CD38 CD56 CD27 CD19 CD117 CD81
2 CD45 CD138 CD38 CD56 CD229 CD19 CyIgκ CyIgλ
APC C750
3 1 CD45 CD138 CD38 CD56 CD27 CD19 CD117 CD81
2 CD45 CD138 CD38 CD56 CD229 CD19 CyIgκ CyIgλ
HV450
4 1 CD138 CD27 CD38 CD56 CD45 CD19 CD117 CD81
2 CD138 CD27 CD38 CD56 CD45 CD19 CyIgκ CyIgλ
BV421 BV510
5 1 CD138 CD27 CD38 (ME) CD56 CD45 CD19 CD117 CD81
2 CD138 CD27 CD38 (ME) CD56 CD45 CD19 CyIgκ CyIgλ
10-color panel version BV421 BV510 BV605 FITC PE PerCPCy5.5 PECy7 APC APCAF700/AF700 APC C750
1 CD138 CD27 CyIgλ CD38 CD56 CD45 CD19 CD117 CyIgκ CD81
2 CD138 CD27 CD117 CD38 CD56 CD45 CD19 CyIgκ CyIgλ
3 CD138 CD27 CD45 CD38 (ME) CD56 CyIgλ CD19 CD117 CD81 CyIgκ
Abbreviations: APC, allophycocyanin; A700, alexa ﬂuor 700; BV421, brilliant violet 421; BV510, brilliant violet 510; BV605, brilliant violet 605; Cy, cytoplasmic;
C750, C750 dye; Cy5.5, cyanin5.5; Cy7, cyanin7; FITC, ﬂuorescein isothiocyanate; HV450, Horizon V450; HV500C, Horizon V500C; H7, Hillite 7; Ig, immunoglobulin;
MRD, minimal residual disease; ME, multi-epitope; PacB, paciﬁc blue; PacO, paciﬁc orange; PE, phycoerythrin; PerCP, peridinin–chlorophyll–protein. Changes
from previous versions in markers or ﬂuorochromes are highlighted in italics.
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vs FACS-lyse protocols) associated with similar numbers (P40.05)
of cell doublets (Supplementary Figure 2B). Of note, detailed
analysis of the speciﬁc recovery of the major leukocyte popu-
lations (that is, eosinophils, neutrophils, monocytes, mature
lymphocytes and nucleated red cells) as well as of nPC and
aPC showed no signiﬁcant differences between the condi-
tions evaluated (P40.05), except for higher nPC percentages for
the bulk-lysis protocol B1 (Supplementary Figures 2C and D).
Therefore, the bulk-lysis procedure including a FACS-lysing-
ﬁxation step and 0.5% bovine serum albumin (protocol
A1 in Supplementary Figure 2) was selected as the reference
SOP and used to further titrate the individual antibody rea-
gents selected, for staining of ⩾ 107 cells/tube (Supplementary
Table 5).
Validation of the EuroFlow-based NGF MM-MRD method
The ﬁnal NGF MM-MRD approach described above was validated
against conventional 8-color ﬂow-MRD in 228 MM BM samples
studied at diagnosis (n= 66) or after therapy (n= 162), particularly
focusing on 110 BM samples from patients in VGPR or CR/sCR.
A strong correlation was found between both methods in diagnostic
and follow-up samples with relatively high tumor burden from
patients in partial response, stable disease and progressive disease
(ρ= 0.96; Po0.001; Figure 2a). Most importantly, a fairly good
overall correlation was also observed among cases in VGPR and
CR/sCR (ρ= 0.77; Po0.001; Figure 2b), albeit signiﬁcantly different
rates of MRD+ samples were detected with both methods: 37/110
(34%) for conventional ﬂow-MRD vs 52/110 (47%) for EuroFlow-
NGF, respectively (P= 0.003; Figure 2b). This was due to a relatively
Figure 2. Validation of the new NGF method for MRD detection in MM against both conventional 8-color ﬂow-MRD (a, b) and NGS (c),
including expert-based vs automated NGF-MRD data analysis (d). In a, the comparison between NGF and conventional ﬂow-MRD is shown for
diagnostic and follow-up samples from patients with stable/progressive disease and partial response (n= 118), while in b the two ﬂow
methods are speciﬁcally compared for follow-up samples from MM patients in VGPR and CR/sCR (n= 110). (d) The correlation between expert-
based vs automatic PC identiﬁcation MRD levels in the same 110 BM samples as those of b. In turn, c shows the correlation between NGS and
NGF MRD levels for those 27 (low level) MRD samples analyzed by both methods. *Samples proven polyclonal by Cy Ig κ/λ staining (2/2 and
2/3 in a and b, respectively). ƚSamples positive by NGS at the limit of quantitation of the technique. White and black circles in b and d
represent NGF MRD levels below and above the limit of quantitation of the technique, respectively.
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high number of discrepant cases, which were mostly MRD+ by
EuroFlow-NGF but MRD− by conventional ﬂow: 18/21 (86%) vs
3/21 (14%) discrepant samples, respectively. Of note, such
discrepant NGF+ cases typically showed MRD levels o10− 4
by EuroFlow-NGF with median (range) MRD levels of 0.001%
(0.0001–0.03%) vs 0.02% (0.0008–1.79%) for MRD+ cases by both
methods (Po0.001; Figures 2b and 3). Interestingly, in three
MRD− cases by EuroFlow-NGF, MRD+ results at relatively high
levels (median of 0.01%; range: 0.006–0.02%) were observed by
conventional MRD-ﬂow (Table 2). Evaluation of cytoplasmic κ/λ
expression in the suspicious PC from these three patients by
EuroFlow-NGF, demonstrated the polyclonal nature of the
suspected aPC in 2/3 cases, indicating false-positivity in conven-
tional ﬂow-MRD; in contrast, no clear explanation was found for
the discrepant results observed in the other patient. Overall, the
frequency of aberrant expression proﬁles for individual markers on
clonal PC by NGF, was as follows: CD45, 96%; CD19, 96%; CD56,
96%; CD27, 89%; CD81, 79%; CD38, 77%; CD117, 48% and CD138,
37%. In 8/52 MRD+ cases conﬁrmation of light chain restriction
among small numbers of suspicious PC carrying slightly aberrant
phenotypes was required. No signiﬁcant differences were
observed in the validation phase between the participating
centers with respect to rate and type of MRD discrepant cases
(P= 0.63). Importantly, in all but 7/110 cases, 47 × 106 cells were
evaluated (median 10.4 × 106 cells) with an impact on the
sensitivity of the method because of not reaching the LOD in
only 2 cases (1.8%). Interestingly, an alarm for decreased
percentage of CD117hi mast cells (⩽ 0.002%) suggesting blood
contamination, was observed in 17/110 samples, 11/17 MRD− and
6/17 MRD+ samples (Table 3).
Automatic identiﬁcation and enumeration of aPCs showed an
excellent correlation with expert-based gating, also in VGPR and
CR/sCR cases (ρ= 0.96; Po0.001; Figure 2d). However, due to the
minimum number of events required by the software algorithm,
aPC were not identiﬁed in 3/110 cases (2.7%) with low MRD levels
by NGF (and MRD− by conventional ﬂow-MRD) -median % aPC
(range): 0.0006% (0.0001–0.005%; Figure 2d)-.
Parallel assessment of MRD by NGF and NGS in a subset of 31
samples showed a higher applicability for the EuroFlow-NGF
approach: 31/31 (100%) vs 27/31 (87%) cases, respectively
(Po0.001). Among those 27 cases assessed by both methods
(22 of them with MRD levels ⩽ 10− 4), a good correlation was found
between the percentage of residual aPC by NGF and NGS (ρ= 0.62;
P= 0.001; Figure 2c). However, NGF showed a higher sensitivity
than NGS with 19/27 (70%) vs 14/27 (52%) MRD+ samples
(P= 0.06) with higher MRD levels -mean percentage ± s.d. MRD+
cells of 0.01 ± 0.04% vs 0.006 ± 0.02% (P¼ 0.07), respectively-. This
was due to 7/27 discrepant cases including six MRD+ by NGF and
MRD− by NGS: median (range) percentage aPC of 0.001% (0.0002–
0.07%) and one MRD+ by NGS (0.0004% aPC) and negative (LOD
o0.0002% aPC) by NGF (Figures 2c and 3). In fact, 8/27 samples
(30%) were NGF-positive (quantiﬁable), but NGS-negative or
discrepantly low positive.
From the prognostic point of view, MM patients who were
MRD− by NGF had a signiﬁcantly (P= 0.01) longer PFS vs MRD+
cases -75% PFS not reached (NR) vs 10 months; Figure 4a-,
including also those that were MRD+ by NGF and MRD− by
conventional 8-color ﬂow (75% PFS of 10 months; Figure 4b);
similar results were observed when the analysis was restricted to
patients in CR/sCR (P= 0.02; 75% PFS NR vs 7 and 5 months,
respectively; Figures 4c and d). Of note 2/6 patients who were
MRD+ by NGF and MRD− by NGS also showed disease progression,
while the only NGF−/NGS+ discrepant patient remained in
continuous CR after 14 months follow-up.
Figure 3. Illustrating graphical representations of the performance of the NGF method based on the analysis of (merged) data ﬁles
corresponding to a BM MM sample (4107 cells) with low level MRD stained with the NGF-MM MRD panel (Version 5). Left panels show
classical bivariate dot plot representations in which PC (blue and red dots) were gated using a conventional manual analysis strategy. nPC
(blue dots) display characteristic normal patterns of expression for the surface membrane markers used, with a cytoplasmic (Cy) Igκ vs CyIgλ
ratio of 1.6. In contrast, clonal/aberrant PC (red dots) can be clearly discriminated from nPC based on their more homogeneous phenotypic
proﬁle, the presence of myeloma-associated phenotypes (CD138hi, CD38dim, CD19−, CD81−, CD117− and CD27dim) and a restricted pattern of
expression of CyIgλ. Other non-PC BM populations are depicted as gray dots. In turn, the top right panel shows the results of principal
component analysis –automatic population separator 1 (APS1) view of principal component 1 (PC1) vs PC2— demonstrating a clearly different
overall immunophenotypic proﬁle of normal and aPCs in this sample. In this later plot, circles represent median values for all phenotypic
parameters measured in the two tubes but CyIgs, while inner (doted) and outer (solid) lines represent the ﬁrst and second s.d. of the
distribution of the PC events in the multidimensional space, respectively. The table in the right illustrates the top 6 parameters contributing to
the separation between nPC and aPC in the above PC1 vs PC2 plot and their percentage contribution to the separation. Please note that, in
this sample, PC corresponded to 0.005% of all nucleated BM cells; in turn, aberrant PC (127 PC events) corresponded to 0.001% of the whole
BM cellularity with an assay sensitivity (in the quantitative range) of o5 × 10− 6.
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DISCUSSION
MRD detection in BM has proven clinically meaningful for MM
monitoring after therapy, particularly to predict outcome of
patients that reach CR12–16,29 independently of therapy.22,53
Currently, several different ﬂow- and PCR-based MRD approaches
are available.30 Flow-MRD has clear advantages vs PCR-based
methods because of its relative simplicity, high speed, greater
clinical applicability and worldwide availability.16,25 However,
major concerns have been recently raised about the lack of
standardization of ﬂow-MRD in MM38 and its lower sensitivity vs
PCR-based approaches, particularly NGS.25,29,53–55
Here we describe an innovative EuroFlow-based high-sensitive,
standardized and validated NGF-MRD method which can be
applied to virtually every MM patient for MRD monitoring in BM
after therapy. Overall, our results show a similar applicability but a
signiﬁcantly increased sensitivity for the novel EuroFlow-NGF
approach vs conventional ﬂow-MRD, with around one fourth of all
MRD-negative samples by conventional ﬂow becoming MRD-
positive by NGF. To the best of our knowledge, this is the ﬁrst time
that a validated high-sensitive ﬂow-MRD assay is described with a
LOD close to 10− 6 (ability to identify down to 20 tumor PCs
among 107 evaluated BM cells) and a limit of quantitation of
o5 × 10− 6 (ability to accurately quantity tumor PC percentages at
levels down to ﬁve cells per million cells, that is, 0.0005%),
calculated following consensus recomendations.42 Importantly,
the EuroFlow-NGF approach provided similar results in different
centers, which further conﬁrms the high standardization level of
the method. From the clinical point of view, despite the (still)
limited follow-up time, the NGF approach already showed a
signiﬁcant prognostic impact on PFS of MM patients, even among
those in CR/sCR, signiﬁcantly improving the predictive clinical
value of conventional ﬂow-MRD.
The greater sensitivity of NGF vs conventional ﬂow-MRD was
mostly due to the use of both an optimized combination of
ﬂuorochromes and antibody reagents for increased speciﬁcity at
very low MRD levels, and the 10-fold increase in the number of
cells evaluated, in the context of fully standardized laboratory
protocols. The two-tube approach proposed also allows conﬁrma-
tion in a second independent measurement, of the clonal nature
of suspicious (low numbers of) PC, through evaluation of the
cytoplasmic κ/λ restriction of phenotypically aberrant PC which
proved to be required in a signiﬁcant number of cases.
Interestingly, the phenotypic markers selected as most informative
Table 3. Distribution of distinct BM-associated populations as identiﬁed by the NGF antibody combination (version 5) and percentages of MRD− and
MRD+ cases with decreased levels
BM-associated cell population (phenotypea) Normal BM range (n= 16),
hemodiluted BM cutoff
% of cases with
low levels
NGF MRD− patients showing
disease progression
TOTAL
MRD− MRD+ Case 1 Case 2
% Mast cells (CD117hi, CD45+, CD81dim, CD38+, SSC/FSCint−hi) 0.006% (0.002–0.03%) 10% 5% 0.0017% 0.0006%
% NRBC (SSC/FSClo, all markers−) 6.4% (2–11.5%) 3% 1% 8% 5%
% CD19− nPC (CD38hi, CD138+, CD45− /+, CD56− /+, CD81− /+,
CD27+, FSC/SSCint)
0.05% (0.003–0.2%) 14% 14% 0.0038% 0.0036%
% CD27+ B Cell precursors (CD19+; CD38++, CD45dim, CD81++,
CD27+, CyIg−, FSC/SSClo)
0.08% (0.004–0.4%) 12% 11% 0.0001% 0.003%
% CD27− B Cell precursors (CD19+; CD38++, CD45dim, CD81++,
CD27−, CyIg−, FSC/SSClo)
0.4% (0.05–2.2%) 11% 13% 0.001% 0.01
% Mature B cells (CD19+; CD38+, CD45dim/+, CD81+, CD27− /+,
CyIg+, FSC/SSClo)
1.6% (0.6–3.5%) 26% 23% 0.1% 0.1%
% Myeloid precursors (CD117+, CD45dim, CD38dim/+; CD81+, SSC/FSCint) 1.8% (0.2–3.6%) 8% 8% 0.3% 0.3%
% Endothelial and mesenchymal cells (CD81hi, CD45−, SSC/FSCint/hi) 0.01% (0.0005–0.08%) 1% 0% 0.02% 0.02%
Abbreviations: BM, bone marrow; FSC, forward scatter; MRD, minimal residual disease; NGF, next generation ﬂow; nPC, normal plasma cells; NRBC, nucleated
red blood cells; SSC, sideward scatter. aMarkers used in the gating strategy.
Table 2. Distribution of aberrant (aPC) and normal (nPC) plasma cells
in BM samples from MM patients in VGPR, CR and sCR with discrepant
MRD results (MRD+ vs MRD−) by NGF vs conventional ﬂow-MRD assays
Case ID Disease
status
Conventional
ﬂow
NGF
% tPC % nPC % aPC % tPC % nPCs % aPC
1 CR 0.01 0.01 0 0.008 0.007 0.0004
2 CR 0.01 0.01 0 0.02 0.02 0.0002
3 CR 0.007 0.007 0 0.007 0.007 0.0003
4 CR 0.04 0.04 0 0.02 0.02 0.0004
5 sCR 0 0 0 0.003 0.002 0.0006
6 CR 0.1 0.1 0 0.1 0.1 0.002
7 CR 0.2 0.2 0 0.2 0.2 0.02
8 sCR 0 0 0 0.002 0.003 0.0002
9 CR 0.9 0.9 0 0.6 0.6 0.005
10 CR 0.2 0.2 0 0.06 0.06 0.0004
11 VGPR 0 0 0 0.01 0.01 0.0007
12 CR 0 0 0 0.01 0.01 0.006
13 sCR 0.2 0.2 0 0.2 0.2 0.005
14 sCR 0.03 0.03 0 0.03 0.03 0.002
15 CR 0.1 0.1 0 0.07 0.04 0.03
16 VGPR 0 0 0 0.009 0.008 0.001
17 CR 0.1 0 0 0.004 0.003 0.001
18 CR 0.04 0 0 0.01 0.01 0.0002
19 CR 0.09 0.08 0.01 0.05 0.05 0
20 CR 0.1 0.1 0.006 0.1 0.1 0
21 CR 0.4 0.3 0.02 0.3 0.3 0
Abbreviations: aPC, aberrant plasma cell; BM, bone marrow; CR, complete
response; MM, multiple myeloma; MRD, minimal residual disease; NGF, next
generation ﬂow; nPC, normal plasma cell; sCR, stringent CR; tPC, total
plasma cells; VGPR, very good partial response.
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did not differ from those considered to be essential by expert
consensus.40,41,48 However, we proved here that selection of
optimal ﬂuorochrome-conjugated antibody clones per marker
could not be predicted by pre-existing (shared) expertise. Thus,
identiﬁcation of the optimal marker combinations for the 2-tube
8-color antibody panel required ﬁve rounds of optimization of
what we already considered initially to be a potentially ‘optimal’
panel (that is, Version 1). Major limitations of suboptimal reagents
were: (i) increased non-speciﬁc and background ﬂuorescence;
(ii) too dim ﬂuorescence intensity; (iii) speciﬁc interactions among
mixed reagents and/or; (iv) suboptimal staining or reduced
reactivity on nPC vs aPCs, particularly on Daratumumab-treated
vs non-treated patients. Altogether, these results indicate that
(extensive) prospective testing is mandatory to deﬁne optimal
combinations of reagents for ﬂow-MRD monitoring in MM, due to
the problems encountered and the signiﬁcantly different staining
proﬁles obtained with distinct combinations of reagents of the
same CD markers. As an example, only two of the many
(n= 9) CD38 antibody clones evaluated proved efﬁcient for
detecting CD38 on PC from Daratumumab-treated MM patients
(Supplementary Figure 1); even more, only one of these two
clones proved to be effective for detecting CD38 on MM PC
treated in vitro with the Isatuximab antibody (Supplementary
Figure 1).
Although the speciﬁc combination(s) of markers used is a key
factor for optimal identiﬁcation of BM PC and discrimination
between nPC and aPC, another critical factor in building a
sensitive ﬂow-MRD technique is the number of cells analyzed.42,56
To the best of our knowledge, this is the ﬁrst report in which
consistently 45 × 106 cells/patient sample (usually 4107 cells)
were investigated. For the most frequently used stain-lyse-and-
then-wash sample preparation ﬂow-MRD procedures, hundred
thousand to 1–2 million cells in ⩽ 300 μl BM are analyzed.
In contrast, the here described EuroFlow SOP assured acquisition
of 4107 events in most MM BM MRD samples, by means of
staining a median of 1.5 ml of total BM sample, with a proven limit
of quantitation for the NGF MRD method of o5 × 10− 6 and a LOD
of o2 cells per million. These features contribute to explain the
higher sensitivity of EuroFlow-based NGF vs conventional ﬂow-
MRD, and NGS. The relatively high frequency of discrepant results
(30%) in the NGF vs NGS comparison among cases with low
(o10− 4) MRD levels, might be caused by suboptimal annealing of
the NGS-PCR primers due to high levels of somatic hypermuta-
tions in the IG genes of nPC and aPC,16,32,34 and deserves further
investigation.
Independently of its potentially greater sensitivity, NGF has
other additional advantages over NGS:37 it is faster (o4 h),
standardized and reproducible, it has a greater applicability
(⩾ 98%), and it does not require a diagnostic sample or patient-
speciﬁc probes, which potentially lead to a lower variability in the
sensitivity reached per patient.16 However, EuroFlow-based NGF
required fresh material analyzed within 24 h after sampling; this is
Figure 4. PFS curves of MM patients grouped according to their BM MRD status as assessed by NGF (a, c) and both NGF and conventional
ﬂow-MRD (b, d). In a and b the impact of the MRD status is shown for MM patients in VGPR, CR and sCR (n= 79), while in c and d, PFS analyses
was restricted to MM patients who were in CR and sCR at the moment of MRD assessment (n= 50).
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feasible in virtually all countries, since the standardized EuroFlow
procedures have now been implemented worldwide. In addition,
the costs of the NGF reagents (∼100 USD) and assay (∼350 USD),
are estimated to be lower than those of NGS (∼350 USD and 700
USD, respectively).16
Importantly, NGF can also provide an overall assessment of the
quality of the patient sample through identiﬁcation of a signiﬁcant
decrease in non-PC BM cell populations (for example, CD117hi
mast cells, CD45− sideward-scatterlo nucleated red blood cells,
CD117+ myeloid precursors, CD19+CD38hiCD45lo B-cell precursors
and CD19− nPC) in hemodiluted BM samples (Table 3) and
through providing full insight in the normal B-cell compartment
via the identiﬁcation of normal BM residual B-cell precursors
(CD19+CD38hiCD45lo and CD45int), immature B-lymphocytes
(CD19+CD45hiCD38lo), naive B cells (CD19+CD38−CD27−), memory
B-lymphocytes (CD19+CD38−CD27+), and nPC (CD19+CD56−,
CD19−CD56− and CD19−CD56lo) in addition to myeloma PC
(Supplementary Figure 3). Of note, decreased numbers of mast
cells were found in 17/110 ⩾ VGPR BM samples, particularly
among MRD− cases, including the only two patients that showed
disease progression (Table 3), pointing out the need for careful
evaluation of MRD− cases for blood contamination. Whether
evaluation of an additional sample from the same patient is
required in the such cases, still remains to be established.
The relatively short time needed for the complete EuroFlow-
NGF procedure (o4 h) can be further reduced by implementing
automatic sample preparation procedures, pre-mixed and dried
antibody cocktails, and software algorithms for automatic data
analysis. Such improvements are ongoing and will further
contribute to prevent diagnostic errors.
A major challenge we faced during the design phase was to
determine whether the 2-tube 8-color NGF approach could be
replaced by a single 10-color tube to decrease reagent costs and
data acquisition time, as suggested by others.57 Direct comparison
of Version 5 of the two 8-color tube antibody panel vs three
different versions of a single 10-color antibody combination
(Supplementary text) showed quite comparable results for both
formats. However, the 2-tube 8-color method emerged as a more
robust assay because (i) higher numbers of cells were measured;
(ii) the conﬁrmatory value of the second tube in case of small
populations of suspicious PC found in the ﬁrst tube; and (iii) the
increased consistency and precision of replicate vs single
measurements.
In summary, here we describe a novel validated EuroFlow-NGF
assay for high-sensitive, fast and standardized quantiﬁcation of
MRD in MM that overcomes previous limitations of conventional
ﬂow-MRD approaches and improves prediction of patient out-
come. This method is ready-to-use and well-suited for implemen-
tation in clinical trials to establish the diagnostic role of
MRD in MM.
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